Conexeu Sciences is developing tissue-regeneration technology to address large-volume tissue restoration needs driven by widespread GLP-1 weight-loss drug use. CEO Miles Harrison discussed in an IPO Edge fireside chat how the company's single bioresorbable regenerative scaffold platform aims to serve multiple markets including wound care, aesthetics, oral health, veterinary medicine, and reconstruction. The company plans to submit a 510(k) application to the FDA in early 2027 for its initial indication, with additional catalysts including data publications, breast program progress, and expansion into dental and veterinary markets. Conexeu's technology is positioned as a potential alternative to silicone breast implants and targets areas where current fillers and injectables fall short.
Conexeu Sciences Inc. Common StockCompany's tissue-regeneration technology targets GLP-1 weight-loss patients, with FDA submission planned.
Castle Biosciences Inc
Ipsen SA
LOréal S.A.